Immunocore Holdings PLC (NASDAQ:IMCR) Beats Q2 2025 Revenue and EPS Estimates with Strong KIMMTRAK Sales Growthchartmill.comImmunocore (IMCR) beat Q2 2025 estimates with $98M revenue (+30% YoY) and a narrower EPS loss. KIMMTRAK sales surged 32%, while pipeline progress and strong cash position ($882.8M) boosted investor confidence.
Why Are Amicus, Immunocore, & Immuneering Stocks Trading Lower On Friday?benzinga.comMorgan Stanley downgrades Amicus Therapeutics, Immunocore, and Immuneering, citing pricing challenges, pipeline updates, and cautious growth outlooks.
3 Fast-Growing Stocks Analysts See Doubling in PriceClinical-stage biotech firms often have massive upside potential, but much of that possible success hinges on successful trials and product launches.
3 Small-Cap Stocks with Significant Growth Potentialinvestorplace.comAs sector rotation continues, it could be time for investors to consider these small-cap growth stocks that institutions love.
